Flecainide Therapy Management

Expected Pharmacologic Effects

The American College of Cardiology recommends that PR interval prolongation, an anticipated effect of flecainide's sodium channel blockade, should be monitored but does not mandate discontinuation in patients with normal cardiac conduction 1, 2
Flecainide prolongs the PR interval as part of its therapeutic mechanism, affecting all major cardiac conduction pathways in the general population 3
The PR interval should be measured at baseline and monitored during therapy, but prolongation itself is not a stopping criterion for patients on flecainide 4, 5

The European Heart Journal guidelines state that a QRS duration increase of ≥25% compared to baseline is the critical threshold that signals potential proarrhythmia risk and mandates either dose reduction or drug discontinuation in patients on flecainide 6
Development of new bundle branch block, particularly left bundle branch block, requires precautions and close monitoring in patients on flecainide 6
The American College of Cardiology and European Heart Journal recommend stopping flecainide immediately if QRS widening ≥25% from baseline or development of sustained monomorphic ventricular tachycardia occurs 6, 3

The American College of Cardiology recommends obtaining ECG after each dose change and calculating percentage change in QRS duration from baseline during dose titration 4, 5
The European Heart Journal guidelines state that regular ECG monitoring to assess QRS duration, PR interval, and QT/QTc interval is necessary during ongoing maintenance therapy 6
The American College of Cardiology and European Heart Journal recommend stopping flecainide immediately if new structural heart disease or reduction in LVEF, symptomatic bradycardia, or high-grade AV block develops 6, 3

The American College of Cardiology recommends focusing monitoring on QRS duration changes, not PR interval changes, as PR prolongation without excessive QRS widening is expected and therapeutic 6, 1, 2
The European Heart Journal guidelines state that failing to obtain baseline ECG makes it impossible to calculate the critical 25% QRS increase threshold and increases proarrhythmic risk 6
The American College of Cardiology recommends avoiding outpatient initiation in patients with symptomatic sick sinus syndrome, AV conduction disturbances, or bundle branch block, and initial conversion should be undertaken in hospital 1, 2

The European Society of Cardiology recommends obtaining a 12-lead ECG to measure baseline PR interval, QRS duration, and QT interval before starting flecainide therapy 7
The European Society of Cardiology suggests an echocardiogram to exclude structural heart disease, assess left ventricular ejection fraction (LVEF), and rule out coronary artery disease, as flecainide is contraindicated in patients with structural heart disease or LVEF <30% 7
Baseline liver function tests, including SGPT/ALT, should be obtained before starting flecainide 8
Serum electrolytes, such as potassium and magnesium, should be checked to ensure normal levels before initiation of flecainide therapy 9

The European Heart Journal recommends regular ECG monitoring upon initiation of flecainide therapy, with specific parameters to monitor including QRS duration, PR interval, and QT/QTc interval 7
An increase in QRS duration of ≥25% compared with baseline is a sign of potential risk of proarrhythmia and requires dose reduction or discontinuation 7
QRS widening should not exceed 150% of pretreatment QRS duration 10
Weekly ECG monitoring is recommended during dose titration or after any dose increase 11

The American Heart Association recommends periodic monitoring of trough plasma levels, with a target therapeutic range of 0.2-1.0 mcg/mL 11
Baseline liver function tests, including SGPT/ALT, should be obtained before starting flecainide, and monitored during therapy, with specific guidelines for isolated SGPT elevation 8

The American College of Cardiology recommends monitoring digoxin levels and reducing digoxin dose when initiating flecainide, as levels typically rise 11
The American College of Cardiology suggests monitoring INR closely and reducing warfarin dose in anticipation of INR increases with concurrent flecainide 11
Medications that increase flecainide levels, including CYP2D6 inhibitors, should be evaluated 8, 9

The European Heart Journal recommends monitoring for ventricular arrhythmias, including ventricular tachycardia, particularly in patients with structural heart disease 7
The American Heart Association suggests monitoring for atrial flutter with rapid ventricular conduction, and recommends concomitant AV node blockade 7, 12

The European Society of Cardiology (ESC) recommends that a QRS widening of ≥ 25 % from a patient’s baseline should be considered the critical threshold for pro‑arrhythmic risk, prompting immediate dose reduction or discontinuation of flecainide. 13

The ACC/AHA/ESC guidelines designate the presence of structural heart disease (e.g., coronary artery disease, heart failure, reduced left‑ventricular ejection fraction) as an absolute contraindication to flecainide therapy. 14, 13, 15
The ESC identifies pre‑existing conduction abnormalities—such as sick sinus syndrome, atrioventricular block, or bundle‑branch block—as high‑risk conditions that contraindicate flecainide use. 13